US Patent 11,707,466: Scope, Claims, Exclusivity and Patent Landscape for Lybalvi Bilayer Tablets

US Patent 11,707,466 covers a coated, immediate-release bilayer tablet combining olanzapine with 10 mg of samidorphan. Its strongest protection is directed to the commercial Lybalvi formulation architecture: separate olanzapine and samidorphan layers, defined microcrystalline cellulose and lactose ranges, selected magnesium stearate levels, rapid dissolution, and, in narrower claims, samidorphan L-malate particle size and olanzapine-stability performance.

The patent does not broadly claim olanzapine, samidorphan, the combination as an active-ingredient concept, or treatment of schizophrenia and bipolar disorder. A competing product would generally need to practice every limitation of at least one asserted claim to create literal infringement risk.

What drug and formulation does US Patent 11,707,466 protect?

The patent protects a fixed-dose olanzapine/samidorphan bilayer tablet corresponding to the four approved Lybalvi strengths:

Olanzapine strength	Samidorphan strength	Covered by claims
2.5 mg	10 mg	Claim 15 only
5 mg	10 mg	Claims 1, 7, 11, 14 and 15
10 mg	10 mg	Claims 1, 8, 11, 14 and 15
15 mg	10 mg	Claims 1, 9, 11, 14 and 15
20 mg	10 mg	Claims 1, 10, 11, 14 and 15

The approved Lybalvi strengths are 5/10 mg, 10/10 mg, 15/10 mg and 20/10 mg olanzapine/samidorphan. The 2.5/10 mg strength is recited in claim 15 but is not among the principal strengths identified in the FDA-approved product labeling cited here.[1]

The active ingredients are separated into two tablet layers:

The first layer contains samidorphan or a salt in an amount delivering 10 mg of samidorphan.
The second layer contains the selected olanzapine dose.
A film coating covers the bilayer tablet.
The formulation is immediate release rather than extended release or delayed release.

The separation of the two active ingredients is central. A monolithic tablet containing both ingredients in one blended layer would not satisfy the bilayer limitation unless the product otherwise met the claim construction applied by a court.

What are the independent claims in US Patent 11,707,466?

Claims 1, 11, 14 and 15 are independent composition claims. They differ materially in breadth.

Claim	Core formulation scope	Key narrowing limitations
1	Coated immediate-release bilayer tablet with olanzapine and 10 mg samidorphan	Defined excipient ranges; 1.5-2 wt% magnesium stearate in samidorphan layer; 1 wt% in olanzapine layer
11	More specific bilayer formulation	13.6 mg samidorphan L-malate; approximately 40 wt% microcrystalline cellulose and 42 wt% lactose in first layer; 40 wt% microcrystalline cellulose and 47 wt% lactose in second layer
14	Bilayer tablet with rapid dissolution	At least 85% release of both actives after 15 minutes at pH 4.5
15	Broadest independent formulation claim	Wider excipient ranges; includes 2.5 mg olanzapine; no magnesium stearate requirement; no explicit dissolution requirement

Claim 15 is the principal breadth claim. It requires:

A coated immediate-release bilayer tablet.
A fixed dose of olanzapine and 10 mg samidorphan.
A samidorphan layer containing approximately 30-45 wt% microcrystalline cellulose and 35-50 wt% lactose or a hydrate.
An olanzapine layer containing approximately 35-45 wt% microcrystalline cellulose and 45-55 wt% lactose or a hydrate.
Olanzapine at 2.5, 5, 10, 15 or 20 mg.

Because claim 15 omits the magnesium stearate limitation, a formulation may fall within claim 15 even if it uses a different lubricant or no magnesium stearate, provided the remaining limitations are met.

How broad are the excipient limitations?

The claims are compositionally specific but leave meaningful formulation latitude.

Samidorphan layer

The principal ranges are:

Ingredient	Claims 1 and 14	Claim 11	Claim 15
Microcrystalline cellulose	About 35-43 wt%	About 40 wt%	About 30-45 wt%
Lactose or hydrate	About 37-43 wt%	About 42 wt% lactose monohydrate	About 35-50 wt%
Magnesium stearate	About 1.5-2 wt%	About 1.75 wt%	Not required
Crospovidone	2 wt% in claim 6	Not required	Not required

Olanzapine layer

Ingredient	Claims 1 and 14	Claim 11	Claim 15
Microcrystalline cellulose	About 38-42 wt%	About 40 wt%	About 35-45 wt%
Lactose or hydrate	About 46-49 wt%	About 47 wt%	About 45-55 wt%
Magnesium stearate	About 1 wt%	About 1 wt%	Not required
Crospovidone	1 wt% in claim 6	Not required	Not required

The percentages are based on the weight of the respective layer, not the total tablet. The claims do not require that the listed ingredients account for 100% of the layer weight. Other excipients may therefore be present, subject to the interpretation of the claims and the specification.

The word "about" creates potential claim-construction disputes. A modest deviation from a stated numerical range may still present infringement risk, particularly if the accused formulation is designed to reproduce the claimed performance and the patent specification supports a flexible interpretation. A substantial movement outside the ranges creates a stronger design-around position, but the doctrine of equivalents may remain relevant.

What dissolution performance is protected?

Claims 2, 3, 13 and 14 add dissolution limitations.

Claim	Dissolution requirement	Test conditions
2	At least 97% olanzapine and samidorphan after 30 minutes	500 mL USP acetate buffer, pH 1.0; USP Apparatus II; 37°C; 75 rpm; three-prong sinker
3	At least 97% olanzapine and samidorphan after 30 minutes	Same test at pH 4.5
13	At least 97% of both actives after 30 minutes	pH 1.0; USP Apparatus II; 37°C; 75 rpm
14	At least 85% of both actives after 15 minutes	500 mL USP acetate buffer, pH 4.5; USP Apparatus II; 37°C; 75 rpm; three-prong sinker

Claims 2 and 3 are narrow performance claims. They require a high release threshold for both ingredients under defined laboratory conditions. Failure to meet 97% release does not avoid infringement of the independent claims, but it may avoid those dependent claims.

Claim 14 is broader from a dissolution perspective because it requires only 85% release after 15 minutes. Its independent formulation language, however, retains the bilayer, active-dose and excipient-range limitations.

A generic developer should test each strength using the precise claimed conditions. Dissolution under a different apparatus, buffer volume, sinker configuration, pH or sampling time does not directly answer whether claims 2, 3, 13 or 14 are met.

What samidorphan salt and particle-size features are protected?

Claim 4 identifies 13.6 mg of samidorphan L-malate as the amount corresponding to 10 mg of samidorphan. This is a practical limitation because the commercial formulation uses samidorphan L-malate rather than 10 mg of free samidorphan.

Claim 12 requires particle-size distribution for samidorphan L-malate within these ranges:

Parameter	Claimed range
D10	About 10-80 µm
D50	About 40-200 µm
D90	About 100-300 µm

Claim 12 depends on claim 11. A product must therefore meet the claim 11 formulation limitations before the particle-size limitation becomes relevant.

Particle size is a potentially effective design-around variable, but it is not automatically dispositive. A manufacturer could avoid claim 12 by using material outside the stated distribution while still falling within claims 1, 14 or 15. Particle-size measurements can also produce disputes based on analytical method, dispersion conditions, agglomeration and sampling.

What stability protection does claim 5 provide?

Claim 5 requires that less than 0.5 wt% olanzapine-degradation impurities be detected after six months under the specified storage condition:

Closed container
250 g silica-gel desiccant
25°C
60% relative humidity
HPLC analysis

This is a stability-performance limitation, not merely a requirement to include a desiccant. The claim requires the measured impurity result after the defined storage period.

The condition is commercially relevant because olanzapine is susceptible to degradation and the bilayer design separates the two active ingredients and their respective excipient environments. A competing product using a different package, desiccant quantity or storage condition may not satisfy the exact claim limitation, although the underlying formulation may still fall within claim 1, 11, 14 or 15.

How strong is the patent estate for a generic challenger?

The patent has a layered claim structure:

Claim 15 provides the broadest formulation coverage.
Claims 1 and 14 add narrower but commercially realistic excipient and performance combinations.
Claim 11 targets a formulation close to the specified commercial composition.
Claims 2, 3 and 13 provide high-dissolution fallbacks.
Claims 4, 6 and 12 add salt, excipient and particle-size limitations.
Claims 7-10 separately cover the 5, 10, 15 and 20 mg olanzapine strengths.
Claim 5 adds a stability-performance fallback.

This structure increases litigation value because a challenger may avoid one claim but remain exposed to another. The estate is strongest against a product that copies the bilayer architecture, uses lactose and microcrystalline cellulose in the claimed ranges, uses 10 mg samidorphan L-malate, and is engineered to match Lybalvi dissolution.

The estate is weaker against:

A non-bilayer tablet.
A formulation using materially different filler systems.
A product with excipient percentages outside the broad claim 15 ranges.
A formulation using a different samidorphan salt or free samidorphan.
A product that does not deliver 10 mg samidorphan.
A product with a materially different olanzapine release profile.

Those design choices may create regulatory comparability issues even if they reduce patent exposure.

What FDA regulatory and Orange Book issues apply?

Lybalvi received FDA approval on May 28, 2021, for schizophrenia and bipolar I disorder in adults.[1] The product combines olanzapine, an atypical antipsychotic, with samidorphan, an opioid antagonist intended to reduce olanzapine-associated weight gain.

For an ANDA applicant, the relevant pathway is a fixed-combination generic referencing Lybalvi. The applicant would need to address listed patents through one or more of the statutory certifications under section 505(j), including a Paragraph IV certification for patents it believes are invalid, unenforceable or not infringed.[2]

The relevant regulatory issues include:

Whether US 11,707,466 is listed in the FDA Orange Book for the reference product.
Whether the listing carries a formulation, composition or method-of-use code.
Whether the proposed generic uses the same bilayer architecture and excipient ranges.
Whether the ANDA demonstrates bioequivalence despite formulation and layer differences.
Whether the listed patent has an expiration date that extends beyond the applicable regulatory exclusivity period.

A Paragraph IV notice alleging noninfringement or invalidity could trigger a 45-day period for the patent holder to file suit. A timely suit can impose a 30-month stay of final ANDA approval, subject to statutory exceptions and court developments.[2]

The patent itself is a formulation patent. It does not, based on the supplied claims, claim the approved treatment methods for schizophrenia, bipolar disorder or olanzapine-associated weight gain.

When does Lybalvi lose regulatory and patent exclusivity?

The principal FDA approval date is May 28, 2021.[1] The approval date alone does not establish the patent expiration date.

US 11,707,466 issued on August 22, 2023. Its enforceable term depends on the patent-family priority and nonprovisional filing history, terminal disclaimers, patent-term adjustment and any applicable patent-term extension. Those data are not contained in the claims supplied here. The claims therefore support a scope analysis but do not independently establish a reliable expiration date.

Regulatory exclusivity and patent exclusivity are separate:

Exclusivity type	Relevance to Lybalvi
New chemical entity exclusivity	May restrict ANDA submission for the applicable period if samidorphan qualified for NCE treatment
New clinical investigation exclusivity	May affect approval of certain changes or uses supported by qualifying clinical studies
Formulation patent protection	May delay approval or launch if the listed patent is asserted successfully
Orphan exclusivity	Not established by the supplied claims or the cited FDA approval information
Pediatric exclusivity	Requires a specific FDA grant and is not established here

A generic may be able to submit an ANDA before patent expiration through a Paragraph IV certification, but approval and launch depend on FDA exclusivity, litigation, settlement terms and the applicant’s certification strategy.

Which companies are challenging the patent?

The supplied claims and cited FDA materials do not establish a current Paragraph IV challenger, ANDA applicant, patent litigation docket, or settlement agreement involving US 11,707,466. No competitor can be identified from the patent text alone.

The relevant competitive group consists of:

Alkermes, the commercial sponsor of Lybalvi.
Generic pharmaceutical companies developing fixed-dose olanzapine/samidorphan products.
Manufacturers developing alternative bilayer, multilayer or non-bilayer formulations.
Suppliers of samidorphan, samidorphan L-malate and specialized excipient systems.

Biosimilar risk is not relevant. Lybalvi is a small-molecule drug product, not a biologic. The principal post-exclusivity threat is an ANDA-based generic, not a biosimilar or interchangeable biological product.

What patent litigation and settlement risks matter?

The most important litigation questions are claim-specific:

Whether a proposed product has two distinct tablet layers.
Whether each layer falls within the claimed excipient ranges.
Whether the product contains 10 mg samidorphan, calculated from the salt used.
Whether the formulation is immediate release and film coated.
Whether the product meets the claimed dissolution or stability limitations.
Whether the accused product uses the claimed olanzapine strengths.
Whether any differences avoid literal infringement but remain vulnerable under the doctrine of equivalents.

A settlement could provide a licensed launch date, but no settlement terms are established by the supplied record. License arrangements involving samidorphan technology, manufacturing know-how or other patent families could also affect commercial freedom to operate without appearing in the claims of US 11,707,466.

What generic launch scenarios exist?

Early Paragraph IV launch

A generic applicant could challenge the patent before expiration and seek approval after resolving the 30-month-stay period or prevailing in litigation. The applicant’s strongest noninfringement position would likely involve a formulation outside the claim 15 ranges or a non-bilayer architecture.

At-risk launch

An applicant could launch before final patent resolution after a favorable court ruling, dismissal, settlement authorization or other legal event. This creates damages and injunction exposure if the patent is later upheld and infringed.

Formulation design-around

A company could develop a product with:

A single layer rather than two layers.
Different fillers, such as mannitol, dibasic calcium phosphate or starch-based systems.
Excipient concentrations outside the broad claim 15 ranges.
A different samidorphan salt or particle-size distribution.
A different coating or release design.

The regulatory burden may increase because a substantially different formulation can create more complex bioequivalence and manufacturing comparability questions.

Post-expiration launch

The lowest patent risk generally occurs after expiration of all relevant listed patents and resolution of regulatory exclusivity. A commercial launch assessment must examine the entire Orange Book estate, not US 11,707,466 alone.

How does US 11,707,466 compare with a conventional olanzapine patent?

A conventional olanzapine patent may cover the active compound, polymorph, salt, formulation, manufacturing process or treatment method. US 11,707,466 is narrower in subject matter but closer to the finished product.

Issue	US 11,707,466	Conventional olanzapine patent
Active ingredient	Covers olanzapine only as part of combination tablet	May cover olanzapine itself
Samidorphan	Requires 10 mg dose or equivalent salt amount	Usually not required
Dosage form	Coated immediate-release bilayer tablet	May cover tablet, capsule or other form
Excipient system	Central to most claims	May be absent
Dissolution	Expressly claimed in dependent claims	May not be claimed
Manufacturing process	Not expressly claimed in supplied claims	May be separately protected
Method of use	Not expressly claimed in supplied claims	May be separately protected
Generic risk	Highest for copied bilayer formulation	Depends on product and use

Key Takeaways

US 11,707,466 is a formulation patent directed to a coated immediate-release bilayer olanzapine/samidorphan tablet.
Claim 15 is the broadest independent claim because it omits magnesium stearate and covers wider excipient ranges.
Claims 1 and 11 more closely target the commercial formulation, including samidorphan L-malate and specific lubricant levels.
Claims 2, 3, 13 and 14 add dissolution-performance protection.
Claim 5 adds a six-month olanzapine-stability limitation.
Claims 7-10 separately cover 5, 10, 15 and 20 mg olanzapine strengths.
Claim 15 also recites a 2.5 mg olanzapine strength.
The patent does not, based on the supplied claims, cover treatment methods, samidorphan alone, olanzapine alone, or biosimilar products.
The principal commercial threat is an ANDA applicant using a non-bilayer or materially redesigned formulation.
The patent expiration date cannot be determined reliably from the claims alone; the complete family, priority, terminal-disclaimer and patent-term-adjustment records control.
FDA approval for Lybalvi occurred on May 28, 2021.[1]

FAQs About US Patent 11,707,466 and Lybalvi

Does US 11,707,466 cover all olanzapine and samidorphan tablets?

No. It requires a coated immediate-release bilayer tablet with defined active doses and, in most independent claims, specified excipient ranges.

Can a generic avoid the patent by changing magnesium stearate?

Possibly for claims 1 and 11, but not necessarily for claim 15, which does not require magnesium stearate. The generic would still need to avoid the remaining bilayer, dose, coating and excipient limitations.

Is samidorphan L-malate required by every claim?

No. Claims 1, 14 and 15 permit samidorphan or a pharmaceutically acceptable salt in an amount delivering 10 mg samidorphan. Claim 11 and dependent claim 4 specifically address samidorphan L-malate.

Does the patent cover Lybalvi’s clinical uses?

The supplied claims do not recite schizophrenia, bipolar disorder, weight gain, opioid use, or another method of treatment. They are directed to the tablet formulation.

Is a biosimilar relevant to Lybalvi patent risk?

No. Lybalvi is a small-molecule combination drug. The relevant competitor pathway is an ANDA generic, not a biosimilar application.

References

U.S. Food and Drug Administration. (2021). Lybalvi prescribing information. FDA.
U.S. Code. (2023). 21 U.S.C. § 355: New drugs.
United States Patent and Trademark Office. (2023). U.S. Patent No. 11,707,466. Washington, DC: U.S. Department of Commerce.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021		RX	Yes	Yes	11,707,466	⤷ Start Trial	Y				⤷ Start Trial
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No	11,707,466	⤷ Start Trial	Y				⤷ Start Trial
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,707,466	⤷ Start Trial	Y				⤷ Start Trial
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	11,707,466	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	4243768	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2022101444	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,707,466

Which drugs does patent 11,707,466 protect, and when does it expire?

Summary for Patent: 11,707,466